National Institute of Allergy and Infectious Diseases (NIAID): Infections trials
The registry lists 308 Infections studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 12 are open to participants now and 41 have results posted.
Phase 1 72Phase 2 88Phase 3 44Phase 4 5No phase 108(a study in two phases counts in both)
Studies
Page 4 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZTCompletedNCT00000653Phase 2
- A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV TherapyCompletedNCT00000651Phase 3
- An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV InfectionCompletedNCT00000647Not applicable
- A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDSCompletedNCT00000644Phase 2
- A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.CompletedNCT00000641Phase 2
- Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous InfectionCompletedNCT00000638Not applicable
- Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous InfectionCompletedNCT00000636Not applicable
- Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical TrifluridineCompletedNCT00000635Not applicable